ID
16702
Beskrivning
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Relapse Report
Länk
https://clinicaltrials.gov/ct2/show/NCT00373425
Nyckelord
Versioner (1)
- 2016-08-01 2016-08-01 -
Uppladdad den
1 augusti 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Beskrivning
New Lesion Specification
Beskrivning
Lesion number
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0221198
- UMLS CUI [1,2]
- C0750480
Beskrivning
Provide relevant code number for Method of Evaluation and Disease Site. lf "Other'' applies, use code 99 and specify.
Datatyp
integer
Alias
- UMLS CUI [1]
- C2911685
Beskrivning
Method of Evalution
Datatyp
text
Alias
- UMLS CUI [1]
- C2911685
Beskrivning
Site of Lesion
Datatyp
integer
Alias
- UMLS CUI [1]
- C0449685
Beskrivning
Disease Site
Datatyp
text
Alias
- UMLS CUI [1]
- C0449685
Beskrivning
Date of Evaluation
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0221198
- UMLS CUI [1,3]
- C0031809
Similar models
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0750480 (UMLS CUI [1,2])
C0221198 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,3])